The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks for posting this Bet. Can’t say I understand it all, but a couple of thoughts came to mind.
1. Is it competition or compatible with AVA6k?
2. Chemotoxin resistance of cancer cells to Dox is mentioned in addition to its other side effects. So I wonder if AVA6k also reduces chemotoxin resistance of cancer cells. I can’t recall this being mentioned but it would be good if it does and some numbers attributed to it.
Mowzer, perhaps we should not consider ‘therapeutic’ until we know how much better it is. Some data.
As for the LFT the Mologic antibodies did come to mind when I first heard about pulling the LFTs. But I have a box of useless Avacta LFTs in my junk cupboard that were sold to me months earlier on the basis of using Avacta’s marvellous Affimer. There was no mention of antibodies. Event timing can confuse the best.
Mowzer, agree it sounds great and is why I’m still invested. But I do have some nagging doubts when thinking back to the LFT glory days. I ask myself why is Avacta so shy with its price sensitive data? Why are they keeping it back from us? As Tim says, AS must be basing his words on data.
On the plus side and probably the reason I think it’s still a good bet, even at the same therapeutic levels as plain Dox the January RNS says AVA6k is a good improvement. So should sell like crazy.
“AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed”
It reminds me of the Remain v Leave debate and I wonder if all arguments have similar traits. It seems that when exhausted of rational argument they use three lines of attack, either directly or implied.
1. They are thick and so do not understand.
2. They are motivated by financial skullduggery.
3. Abuse.
Check it out.
I don’t find it a monstrously ignorant comment and my wife died from a combination of cancer and chemotherapy. I would have happily stepped forward to take experimental shots so my wife could too. I wish they could stop *****footing around and start saving many lives soon.
Not everyone has forgotten that ‘we can sell as many LFTs as we can make, Affimers can be quickly adapted to detect mutations, much quicker than antibodies and then oops we’ve been using the wrong antibody.